Congratulations to our client Calidi Biotherapeutics for appointing Eric Poma as Chief Executive Officer.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company pioneering the development a new generation of targeted immunotherapies. The company’s proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.
C1 Team: Christos Richards & James Reynolds